Jen Smith

Phase 3 studies presented at the ESMO Congress 2023 may change the way gynecologic cancers are treated, according to researchers.

The American Cancer Society has updated its guidelines for lung cancer screening to expand the population of patients who should be screened.

Researchers have found evidence to suggest that patients with metastatic non-small cell lung cancer have unique gut microbiomes.

New data suggest that, from 1990 to 2019, the global incidence of early-onset cancer increased by nearly 80%, and the rate of early-onset cancer deaths increased by nearly 30%.

Neoadjuvant camrelizumab in combination with either platinum-doublet chemotherapy or apatinib has demonstrated efficacy in stage II-III NSCLC, according to researchers.

The CAR T-cell therapy ARI0002h can produce durable responses in patients with relapsed or refractory multiple myeloma, a pilot study suggests.

Adding perioperative nivolumab to neoadjuvant chemotherapy improves outcomes in patients with resectable stage IIIA-B NSCLC, a phase 2 trial suggests.

Adding niraparib to first-line treatment with AAP can improve outcomes in patients with mCRPC and HRR alterations, a phase 3 trial suggests.

Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests.

As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.